| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5396826ac8c36d31e3eb53c9ef088a68 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-866 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-39 |
| filingDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f92e6206d719f022d8683907443690a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b0d440259daae2d690ecdb259d4f549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fcbc1fccefaa43f662141f243da7745 |
| publicationDate |
2019-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190000040-A |
| titleOfInvention |
Hydrogel composition for transplanting pancreatic islet cells and pharmaceutical composition for treating diabetes comprising the same |
| abstract |
The present invention relates to a hydrogel composition for pancreatic islet cell transplantation and a pharmaceutical composition for treating diabetes comprising the same. The hydrogel of the present invention is configured to further include not only pancreatic islet cells but also microspheres encapsulating tacrolimus and liposomal claudonate to inhibit acute immune response upon transplantation of pancreatic islet cells, When the hydrogel was subcutaneously injected, it was confirmed that blood glucose was maintained constant over a long period of time. Therefore, the present invention is expected to contribute to the treatment of diabetes by protecting pancreatic islet cells from in vivo immune response and improving the success rate of pancreatic islet cell transplantation. |
| priorityDate |
2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |